[go: up one dir, main page]

MX2012000757A - Analogos de factor de crecimiento insulinoide tipo 1 (igf-1) que tienen sustitucion de aminoacidos en la posicion 59. - Google Patents

Analogos de factor de crecimiento insulinoide tipo 1 (igf-1) que tienen sustitucion de aminoacidos en la posicion 59.

Info

Publication number
MX2012000757A
MX2012000757A MX2012000757A MX2012000757A MX2012000757A MX 2012000757 A MX2012000757 A MX 2012000757A MX 2012000757 A MX2012000757 A MX 2012000757A MX 2012000757 A MX2012000757 A MX 2012000757A MX 2012000757 A MX2012000757 A MX 2012000757A
Authority
MX
Mexico
Prior art keywords
analogues
igf
insulin
amino acid
growth factor
Prior art date
Application number
MX2012000757A
Other languages
English (en)
Inventor
Zheng Xin Dong
Nicholas C Prairie
Maria L Ufret
Jundong Zhang
Deborah Rothman
Jeanne Mary Comstock
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MX2012000757A publication Critical patent/MX2012000757A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)

Abstract

La presente invención se relaciona con análogos novedosos de factor de crecimiento insulinoide tipo 1 (IGF-1), composiciones farmacéuticas que contienen dichos análogos, y el uso de dichos análogos para el tratamiento de condiciones mediadas por receptor de IGF-1, tales como la estatura corta, terapia de diabetes, tratamiento de enfermedad neurodegenerativa y reparación de cartílago. Más particularmente, la presente invención se relaciona con análogos novedosos de IGF-1 que tienen una sustitución de aminoácidos en la posición 59, ej., (Asn59)higo-1(1-70)-OH (Sec. No. 1), y otra(s) sustitución(es) como aquí se define.
MX2012000757A 2009-07-22 2010-07-22 Analogos de factor de crecimiento insulinoide tipo 1 (igf-1) que tienen sustitucion de aminoacidos en la posicion 59. MX2012000757A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27154909P 2009-07-22 2009-07-22
PCT/US2010/002062 WO2011011072A2 (en) 2009-07-22 2010-07-22 Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59

Publications (1)

Publication Number Publication Date
MX2012000757A true MX2012000757A (es) 2012-08-03

Family

ID=43499582

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000757A MX2012000757A (es) 2009-07-22 2010-07-22 Analogos de factor de crecimiento insulinoide tipo 1 (igf-1) que tienen sustitucion de aminoacidos en la posicion 59.

Country Status (13)

Country Link
US (1) US8759299B2 (es)
EP (1) EP2456788B1 (es)
JP (2) JP5571186B2 (es)
KR (1) KR101417872B1 (es)
CN (1) CN102510757B (es)
AU (1) AU2010275010B2 (es)
BR (1) BR112012001363A2 (es)
CA (1) CA2768621C (es)
ES (1) ES2562260T3 (es)
MX (1) MX2012000757A (es)
RU (1) RU2511577C2 (es)
UA (1) UA103104C2 (es)
WO (1) WO2011011072A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101417872B1 (ko) * 2009-07-22 2014-07-09 입센 파마 에스.에이.에스 59번 위치에 아미노산 치환을 포함하는 인슐린 유사 성장 인자-1(ｉｇｆ-1)의 유사체
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
WO2013086786A1 (zh) * 2011-12-15 2013-06-20 Qin Shulin 具有降血糖作用的化合物、组合物及其用途
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
US20250102495A1 (en) 2022-01-24 2025-03-27 Oak Hill Bio Ltd Lot release assays for igf-1/igfbp complexes
CN116754678B (zh) * 2023-06-19 2025-09-16 杭州度安医学检验实验室有限公司 一种血液中胰岛素样生长因子检测样本的处理及检测方法
CN117589998B (zh) * 2023-10-09 2025-11-18 融智生物科技（青岛）有限公司 胰岛素样生长因子i变体的定量检测试剂盒
CN117589997B (zh) * 2023-10-09 2025-11-21 融智生物科技（青岛）有限公司 Igf-1变体的定量检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
JPS60501989A (ja) * 1983-08-10 1985-11-21 アムジエン インシュリン様成長因子の微生物発現
US4888286A (en) * 1984-02-06 1989-12-19 Creative Biomolecules, Inc. Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
US4745179A (en) 1984-04-02 1988-05-17 Fujisawa Pharmaceutical Co., Ltd. 59 Valine insulin-like growth factor I and process for production thereof
GB8408473D0 (en) * 1984-04-02 1984-05-10 Fujisawa Pharmaceutical Co 59 val-insulin-like growth factor i
US5242811A (en) 1985-03-26 1993-09-07 Biogen, Inc. Production of human somatomedin C
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5824642A (en) 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
PT1053020E (pt) 1998-01-29 2004-06-30 Poly Med Inc Microparticulas absorviveis
WO2000004916A1 (en) 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
AR020650A1 (es) 1998-08-10 2002-05-22 Poly Med Inc Polimeros fosforilados y conjugados de los mismos
JP2002528602A (ja) 1998-11-02 2002-09-03 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ラクトンを保有する吸収性ポリマー
ES2234560T3 (es) 1999-01-06 2005-07-01 Genentech, Inc. Variante mutante del factor de crecimiento de tipo insulina (igf-i).
ES2329220T3 (es) * 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
US20030100505A1 (en) 1999-11-01 2003-05-29 Chiron Corporation Compositions and methods of therapy for IGF-I-responsive conditions
AU2002255508B2 (en) 2001-02-09 2008-04-03 Genentech, Inc. Crystallization of IGF-1
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1608688B1 (en) 2003-03-14 2013-02-27 BioGeneriX AG Branched water-soluble polymers and their conjugates
NZ543934A (en) 2003-05-12 2008-06-30 Affymax Inc Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
EP1670413A4 (en) 2003-08-21 2009-07-08 Tercica Inc PROCESS FOR REDUCING VISCERAL FAT BY INCREASING THE MIRRORS OF THE INSULINARY GROWTH FACTOR (IGF-I)
HUE027218T2 (en) 2003-09-12 2016-10-28 Ipsen Biopharmaceuticals Inc Methods for Treatment of IGF-1 (Insulin-like Growth Factor 1) Deficiency
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
ES2532089T3 (es) 2005-06-02 2015-03-24 Ipsen Biopharmaceuticals, Inc. GH e IGF-1 para el tratamiento de trastornos del crecimiento
WO2007102686A1 (en) 2006-03-06 2007-09-13 Caregen Co., Ltd Peptides having activities of insulin like growth factor-1 and their uses
WO2007141309A2 (en) 2006-06-09 2007-12-13 Novartis Ag Stabilized insulin-like growth factor polypeptides
KR101417872B1 (ko) * 2009-07-22 2014-07-09 입센 파마 에스.에이.에스 59번 위치에 아미노산 치환을 포함하는 인슐린 유사 성장 인자-1(ｉｇｆ-1)의 유사체

Also Published As

Publication number Publication date
KR101417872B1 (ko) 2014-07-09
KR20120093828A (ko) 2012-08-23
RU2012106302A (ru) 2013-08-27
BR112012001363A2 (pt) 2016-11-08
CA2768621C (en) 2016-04-05
UA103104C2 (ru) 2013-09-10
AU2010275010A1 (en) 2012-02-09
HK1170748A1 (zh) 2013-03-08
WO2011011072A3 (en) 2011-04-07
JP5571186B2 (ja) 2014-08-13
CN102510757B (zh) 2015-03-18
EP2456788B1 (en) 2015-12-16
RU2511577C2 (ru) 2014-04-10
JP2014169309A (ja) 2014-09-18
ES2562260T3 (es) 2016-03-03
CN102510757A (zh) 2012-06-20
US20120190616A1 (en) 2012-07-26
WO2011011072A2 (en) 2011-01-27
US8759299B2 (en) 2014-06-24
CA2768621A1 (en) 2011-01-27
AU2010275010B2 (en) 2013-10-24
EP2456788A4 (en) 2012-12-05
JP2012533622A (ja) 2012-12-27
EP2456788A2 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
MX2012000757A (es) Analogos de factor de crecimiento insulinoide tipo 1 (igf-1) que tienen sustitucion de aminoacidos en la posicion 59.
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2011075393A3 (en) Glucagon/glp-1 receptor co-agonists
NZ603811A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
EP2594582A3 (en) Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens
MX2010002460A (es) Complejos de arn y peptidos cationicos para transfeccion y para inmunoestimulacion.
IN2014CN02050A (es)
MX2011008094A (es) Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
PE20140186A1 (es) Analogos de glucagon que presentan actividad de receptor de gip
JP2014508510A5 (es)
WO2008086086A3 (en) Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
RU2008141280A (ru) Агонисты рецептора нейромедина u и их применение
JO3226B1 (ar) مخفف توتر سطحي معاد التشكيل مطور يحتوي على نظائر بروتين مخفف للتوتر السطحي b(sp-b) وبروتين مخفف للتوتر السطحي c (sp-c)
ZA200908445B (en) Reconstituted surfactants having improved properties
EA201101525A1 (ru) Фармацевтическая композиция
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
PE20171380A1 (es) Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
MX2010010495A (es) Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.
WO2010128521A3 (en) Short-chain peptides as parathyroid hormone (pth) receptor agonist
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)
JP5992529B2 (ja) ポリペプチド、足場組成物、軟骨組織修復用組成物、軟骨細胞培養用組成物及びグリコサミノグリカン産生促進用組成物
IN2014KN00866A (es)
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis

Legal Events

Date Code Title Description
FG Grant or registration